Vector Science & Therapeutics Broadens Patent Portfolio with 15 Applications Targeting Precision Therapeutic Delivery Technologies

Vector Science & Therapeutics Corp. announced a significant expansion of its intellectual property portfolio, now comprising 15 patent applications developed and filed over approximately the last two years. This growing portfolio establishes a broad technology estate centered on one of the most persistent challenges in medicine: delivering therapeutic agents—especially peptides and biologics that are difficult to administer outside the gastrointestinal tract—to the right tissue, at the correct concentration, and for the appropriate duration.

The company’s intellectual property strategy is built around a cohesive portfolio of interconnected therapeutic delivery technologies. These patent applications encompass non-invasive, minimally invasive, and locoregional systems designed to overcome biological, anatomical, and patient-compliance barriers that often limit conventional pharmaceutical administration.

Vector’s patent portfolio covers a diverse range of technologies unified by the goal of precision therapeutic delivery. The intellectual property includes innovations in multi-route peptide and biologic delivery, advanced transdermal systems, electrically assisted deep-tissue transport, interferential-hybrid iontophoresis, localized catheter delivery, lyophilized pharmaceutical formulations with point-of-care reconstitution, electrostatic spray administration, magnetic field-assisted delivery, microneedle and intratumoral systems, nanoparticle-enabled therapeutic transport, and sensor-guided treatment platforms.

Several patent applications integrate multiple engineering and pharmaceutical disciplines within a single therapeutic system. These systems combine drug formulation, delivery hardware, electrical or electromagnetic energy, tissue sensing, feedback control, and targeted release mechanisms.

Among the highlighted technologies are advanced therapeutic and peptide delivery systems that address the inherent challenges of administering peptides, biologics, and other complex agents through non-gastrointestinal and non-traditional pathways. These include transdermal, iontophoretic, and lyophilized reconstitution-based systems specifically engineered for peptide formulations that are typically unstable or ineffective when administered orally or systemically.

The portfolio also features deep-tissue transdermal delivery technologies, such as interferential-hybrid iontophoresis systems that combine tissue pre-conditioning with electrically driven therapeutic transport and retention phases. In the area of pain management, Vector has developed opioid-sparing and localized analgesic technologies, including lyophilized multimodal analgesic compositions, integrated reconstitution kits, and localized administration systems designed to support targeted pain relief.

Vector’s precision pancreatic oncology technologies include endoscopic ultrasound (EUS)-guided multimodal therapies, microneedle-tipped intratumoral delivery, conductivity and impedance-guided treatment, transarterial pancreatic delivery, and anchored catheter systems intended for sustained locoregional administration.

In regenerative medicine and tissue repair, the company has developed non-invasive systems that deliver peptide-based regenerative agents to musculoskeletal and peripheral nerve targets. Additionally, Vector’s advanced smart wound care technologies integrate responsive therapeutic release, oxygenation, multi-wavelength phototherapy, and real-time wound monitoring within automated treatment platforms.